What’s the value?
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second ‘steady growth’ period. In the first stage we need to estimate the cash flows to the business over the next five years. Where possible I use analyst estimates, but when these aren’t available I have extrapolated the previous free cash flow (FCF) from the year before. For this growth rate I used the average annual growth rate over the past five years, but capped at a reasonable level. I then discount this to its value today and sum up the total to get the present value of these cash flows.
5-year cash flow forecast
|Levered FCF (₹, Millions)||₹137.80||₹4,724.40||₹6,352.25||₹6,748.30||₹7,169.04|
|Source||Analyst x5||Analyst x5||Analyst x4||Extrapolated @ (6.23%)||Extrapolated @ (6.23%)|
|Present Value Discounted @ 13.4%||₹121.52||₹3,673.84||₹4,356.01||₹4,080.77||₹3,822.93|
Present Value of 5-year Cash Flow (PVCF)= ₹16,055
The second stage is also known as Terminal Value, this is the business’s cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of the GDP. In this case I have used the 10-year government bond rate (7%). In the same way as with the 5-year ‘growth’ period, we discount this to today’s value at a cost of equity of 13.4%.
Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = ₹7,169 × (1 + 7%) ÷ (13.4% – 7%) = ₹119,857
Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = ₹119,857 / ( 1 + 13.4%)5 = ₹63,915
The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is ₹79,970. In the final step we divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) or ADR then we use the equivalent number. This results in an intrinsic value of ₹154.19, which, compared to the current share price of ₹155.9, we see that Fortis Healthcare is fair value, maybe slightly overvalued at the time of writing.
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don’t have to agree with my inputs, I recommend redoing the calculations yourself and playing with them. Because we are looking at Fortis Healthcare as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 13.4%, which is based on a levered beta of 0.8. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
Although the valuation of a company is important, it shouldn’t be the only metric you look at when researching a company. For FORTIS, I’ve compiled three fundamental aspects you should further research:
- Financial Health: Does FORTIS have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does FORTIS’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of FORTIS? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St does a DCF calculation for every IN stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here.